top of page

BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region

  • blonca9
  • Nov 4, 2024
  • 1 min read

Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as atrogi, empros pharma, and xspray.



Brought to you by


ree

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page